<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04325971</url>
  </required_header>
  <id_info>
    <org_study_id>38RC20.063</org_study_id>
    <nct_id>NCT04325971</nct_id>
  </id_info>
  <brief_title>Study of Eye Movements as Markers of the Physiological, Cerebral and Cognitive State of Healthy Subjects</brief_title>
  <acronym>EyeProxy</acronym>
  <official_title>Study of Eye Movements as Markers of the Physiological, Cerebral and Cognitive State of Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Grenoble</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Grenoble Institut des Neurosciences</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>GIPSA-LAB</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Grenoble</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this study is the multimodal exploration via eyetracking, MRI and EEG data of&#xD;
      ocular movements and the corresponding brain activation during ecologic visual stimulation in&#xD;
      the healthy population.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cerebral activation following visual stimulation is explored using two neuroimaging&#xD;
      techniques EEG and MRI while eye movements are recorded. Three experiments are performed: in&#xD;
      MR scanner 1) functional localisation of specific areas: LOC, FFA, MT/V5, V1 and V2 and 2) a&#xD;
      saccadic choice experiment; with EEG, replication of the experiments performed in the MR&#xD;
      scanner and 3) an additional experiment of movement detection during the ocular saccades.&#xD;
&#xD;
      Thirty young volunteers (18-40 y old) are involved.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 16, 2020</start_date>
  <completion_date type="Anticipated">September 2023</completion_date>
  <primary_completion_date type="Anticipated">September 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>anonymisation of all data</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Eye movement brain networks</measure>
    <time_frame>24 months</time_frame>
    <description>Identification of the cerebral locus of ocular movement via MRI &amp; EEG</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>OculoDB</measure>
    <time_frame>24 months</time_frame>
    <description>Database repository of healthy population</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Healthy Subjects</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All healthy subject are gathered in one arm</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Neuroimaging</intervention_name>
    <description>MR, EEG recordings</description>
    <arm_group_label>Healthy Subjects</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Normal vision or corrected to normal&#xD;
&#xD;
          -  Social security affiliation&#xD;
&#xD;
          -  Signed consent to participate&#xD;
&#xD;
          -  No pregnancy fo women&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Audition and motor troubles&#xD;
&#xD;
          -  Incapable to decide (Persons mentioned in L1121-5,6 et 8 of public health code)&#xD;
&#xD;
          -  Neurological disorders&#xD;
&#xD;
          -  Pathology affecting oculomotor control&#xD;
&#xD;
          -  MRI incompatibility&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sara MEONI, PH</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Grenoble</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michel Dojat, PhD</last_name>
    <phone>33 456520601</phone>
    <email>michel.dojat@inserm.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nathalie Guyader, PhD</last_name>
    <email>nathalie.guyader@grenoble-inp.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Chu Grenoble Alpes</name>
      <address>
        <city>Grenoble</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michel DOJAT</last_name>
      <phone>33 (0)4 56 52 06 01</phone>
      <email>michel.dojat@inserm.fr</email>
    </contact>
    <investigator>
      <last_name>Sara MEONI, PH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>March 25, 2020</study_first_submitted>
  <study_first_submitted_qc>March 27, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 30, 2020</study_first_posted>
  <last_update_submitted>January 19, 2021</last_update_submitted>
  <last_update_submitted_qc>January 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

